{
  "id": "mhgap#referral_12255b50",
  "content": "PSY1 (update) 1.1 Oral antipsychotic medicines – namely aripiprazole, chlorpromazine, haloperidol,\nolanzapine, paliperidone, quetiapine, risperidone – should be offered for adults with a\npsychotic disorder (including schizophrenia), carefully balancing effectiveness, side-\neffects and individual preference.\nStrong recommendation. Moderate certainty of evidence.\n1.2 Clozapine should be considered for adults with a treatment-resistant psychotic\ndisorder (including schizophrenia) under mental health specialist supervision, carefully\nbalancing effectiveness, side-effects and individual preference.\nConditional recommendation. Moderate certainty of evidence.\nPSY2 (update) Maintenance therapy with antipsychotic medicine for a minimum of 7–12 months\nshould be offered in adults with a first episode of psychosis (including schizophrenia) in\nremission, carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Moderate certainty of evidence.\nPSY3 (update) Maintenance therapy with mood stabilizers or antipsychotic medicines should be\nconsidered for at least six months for adults with bipolar disorder in remission, carefully\nbalancing effectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\nPSY4 (update) Long-acting injection (LAI) antipsychotic medicines – namely fluphenazine, haloperidol,\npaliperidone, risperidone and zuclopenthixol – should be considered as an alternative to\noral antipsychotic medicines for adults with psychotic disorders (including schizophrenia)\nrequiring long-term treatment, carefully balancing effectiveness, side-effects and\nindividual preference.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Referral PSY1 (update) 1.1 Oral antipsychotic medicines – namely aripiprazole, chlorpromazine, haloperidol,\nolanzapine, paliperidone, quetiapine, risperidone – should be offered for adults with a\npsychotic disorder (including schizophrenia), carefully balancing effectiveness, side-\neffects and individual preference.\nStrong recommendation. Moderate certainty of evidence.\n1.2 Clozapine should be considered for adults with a treatment-resistant psychotic\ndisorder (including schizophrenia) under mental health specialist supervision, carefully\nbalancing effectiveness, side-effects and individual preference.\nConditional recommendation. Moderate certainty of evidence.\nPSY2 (update) Maintenance therapy with antipsychotic medicine for a minimum of 7–12 months\nshould be offered in adults with a first episode of psychosis (including schizophrenia) in\nremission, carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Moderate certainty of evidence.\nPSY3 (update) Maintenance therapy with mood stabilizers or antipsychotic medicines should be\nconsidered for at least six months for adults with bipolar disorder in remission, carefully\nbalancing effectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\nPSY4 (update) Long-acting injection (LAI) antipsychotic medicines – namely fluphenazine, haloperidol,\npaliperidone, risperidone and zuclopenthixol – should be considered as an alternative to\noral antipsychotic medicines for adults with psychotic disorders (including schizophrenia)\nrequiring long-term treatment, carefully balancing effectiveness, side-effects and\nindividual preference. Psy1 (update) 1.1 oral antipsychotic medicines – namely aripiprazole, chlorpromazine, haloperidol,\nolanzapine, paliperidone, quetiapine, risperidone – should be offered for adults with a\npsychotic disorder (including sch..."
}